Dogwood Therapeutics Inc (DWTX) FinancialsDWTXFinancialDogwood Therapeutics Inc

Evaluating the bottom line, Dogwood Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -86.30%, provide a clear picture of how effectively DWTX converts its operational activities into shareholder value.

In the context of the broader market, DWTX competes directly with industry leaders such as ACRV and ATRA. With a market capitalization of $90.08M, it holds a leading position in the sector. When comparing efficiency, DWTX's gross margin of N/A stands against ACRV's N/A and ATRA's 69.68%. Such benchmarking helps identify whether Dogwood Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company's current ratio is strong at 5.86, indicating good short-term financial health, and it has a price-to-book ratio of 1.15, suggesting it is reasonably valued compared to its equity. However, the company has reported significant net losses, with a total net income loss of -15,744,616 USD in Q3 2025.